Last reviewed · How we verify
Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs
The purpose of this study is to measure the incidence of hyperpigmentation in Black participants with multiple myeloma (MM) treated with immunomodulatory drugs (IMiDs) compared with Black participants with MM not treated with IMiDs. The study will use de-identified data from electronic medical records in the Flatiron Health database.
Details
| Lead sponsor | Bristol-Myers Squibb |
|---|---|
| Status | COMPLETED |
| Enrolment | 4204 |
| Start date | Sun Oct 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Aug 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Multiple Myeloma
Interventions
- IMiD treatment
- No IMiD treatment
- Systemic therapy
Countries
United States